Section 2: 'For your patient': The challenge for preventive cardiology

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 16, Issue SUPPL. 2, 2009, Pages

  Kotseva, Kornelia ^a   Wood, David ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DIABETES MELLITUS; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; LIFESTYLE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; OBESITY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVASCULARIZATION; SHORT SURVEY; ARTICLE; ATTITUDE TO HEALTH; CLINICAL PRACTICE; EPIDEMIOLOGY; EUROPE; FEMALE; HEALTH PERSONNEL ATTITUDE; HEALTH PROMOTION; MALE; MULTICENTER STUDY; PATIENT EDUCATION; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TIME;

ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PROMOTION; HUMANS; LIFE STYLE; MALE; MULTICENTER STUDIES AS TOPIC; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TIME FACTORS;

EID: 70349268339     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjr.0000359231.80893.ac     Document Type: Short Survey

References (18)

1. Allender S, Scharbotough P, Peto V, Rayner M, Leal J, Luengo-Fernández R, Gray A. European cardiovascular disease statistics: 2008 edition. London: British Heart Foundation; 2008.
2. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006; 27:1610-1619. (Pubitemid 43954923)
3. Lopez A, Mathers CD, Ezzati M, Jamison D, Murray C. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747-1757.
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifcova R, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2): S1-S113.
5. Executive summary: Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2):E1-E40;
6. Eur Heart J 2007; 28:2375-2414.
7. PyöräläK, De Backer G, Graham I, Poole-Wilson PA, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerotic Society and European Society of Hypertension. Eur Heart J 1994; 15:1300-1331.
8. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology Survey of Secondary Prevention of Coronary Heart Disease: principal results. Eur Heart J 1997; 18:1569-1582.
9. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75:334-342.
10. Wood D, De Backer G, Faergeman D, Graham I, Mancia G, PyöräläK. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19:1434-1503.
11. EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme. Eur Heart J 2001; 22:554-572.
12. EUROASPIRE Study Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357:995-1001.
13. De Backer G, Ambrosioni E, Borch-Johnsen K, Boysen G, Burell G, Cifcova R, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl 1):S1-S78.
14. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U., on behalf of EUROASPIRE study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from twenty two European countries. EUROASPIRE Study Group. Eur J Cardiovasc Prev Rehabil 2009; 16:121-137.
15. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U., on behalf of EUROASPIRE study Group. Cardiovascular prevention guidelinesthe clinical reality: a comparison of EUROASPIRE I, II and III surveys in 8 European countries. Lancet 2009; 372:929-940.
16. Kotseva K, Wood D, De Bacquer D, Heidrich J, De Backer G, on behalf of the EUROASPIRE II Study Group. Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II survey. Eur Heart J 2004; 6 (Suppl J):J17-J26.
17. Wood DA, Kotseva K, Jennings C, Mead A, Jones J, Holden A, et al., on behalf of the EUROACTION Study Group. EUROACTION: a European Society of Cardiology demonstration project in preventive cardiology. Eur Heart J 2004; 6 (Suppl J):J3-J15.
18. Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, et al., on behalf of EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, clusterrandomised controlled trial. Lancet 2008; 371:1999-2012.